Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer

Breast Cancer Res Treat. 2018 Feb;168(1):179-187. doi: 10.1007/s10549-017-4581-1. Epub 2017 Nov 25.

Abstract

Purpose: Hormone receptor (HR)-positive breast cancer (BC) shows a poor response to neoadjuvant chemotherapy (NACT). New treatment targets like the Cyclin D1-CDK4/CDK6 complex are promising adjuvant/post-neoadjuvant therapeutic strategies. Evaluating Cyclin D1 overexpression in residual tumor could recognize those patients that benefit most from such post-neoadjuvant treatment. In this study, we determined Cyclin D1 expression in residual BC after NACT. Secondary aims were to correlate Cyclin D1 expression levels with clinicopathological parameters and to assess its prognostic value after NACT.

Methods: We retrospectively assessed the nuclear expression of Cyclin D1 on tissue microarrays with residual tumor from 284 patients treated in the neoadjuvant GeparTrio (n = 186) and GeparQuattro (n = 98) trials. Evaluation was performed with a standardized immunoreactive score (IRS) after selecting a cut-off value.

Results: A high expression level (IRS ≥ 6) of Cyclin D1 was found in 37.3% of the assessed specimens. An increased Cyclin D1 expression was observed in HR-positive tumors, compared to HR-negative tumors (p = 0.02). Low Cyclin D1 levels correlated with clinical tumor stage 1-3 (p = 0.03). Among patients with HR-positive/Her2-negative tumors and high Cyclin D1 expression, a better disease-free survival (DFS) was graphically suggested, but not significant (p = 0.21).

Conclusion: Our study demonstrates a measurable nuclear expression of Cyclin D1 in post-neoadjuvant residual tumor tissue of HR-positive BC. Cyclin D1 expression was not prognostic for DFS after NACT. Our results and defined cut-off suggest that the marker can be used to stratify tumors according to protein expression levels. Based on this, a prospective evaluation is currently performed in the ongoing Penelope-B trial.

Keywords: Breast cancer; Cyclin D-CDK4/CDK6; Cyclin D1; Cyclin D1 TMA; Cyclin D1 overexpression; Neoadjuvant chemotherapy; Prognose Cyclin D1.

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / metabolism*
  • Breast / cytology
  • Breast / pathology*
  • Breast / surgery
  • Breast Neoplasms / mortality
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Cell Nucleus / metabolism
  • Cyclin D1 / analysis
  • Cyclin D1 / metabolism*
  • Disease-Free Survival
  • Female
  • Gene Expression Profiling / methods
  • Humans
  • Mastectomy
  • Middle Aged
  • Neoadjuvant Therapy / methods
  • Neoplasm, Residual
  • Prognosis
  • Receptor, ErbB-2 / metabolism
  • Receptors, Estrogen / metabolism
  • Receptors, Progesterone / metabolism
  • Retrospective Studies
  • Tissue Array Analysis / methods

Substances

  • Biomarkers, Tumor
  • CCND1 protein, human
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Cyclin D1
  • ERBB2 protein, human
  • Receptor, ErbB-2

Grants and funding